title: Pharmacokinetic interactions between darunavir/ritonavir and opioid maintenance therapy using methadone or buprenorphine/naloxone.
authors.affiliation: Johnson & Johnson, 1125 Trenton Harbourton R, Titusville, NJ 08560-1504, USA. vsekar@its.jnj.com
authors.forename: Vanitha
authors.initials: V
authors.lastname: Sekar
authors.forename: Frank
authors.initials: F
authors.lastname: Tomaka
authors.forename: Eric
authors.initials: E
authors.lastname: Lefebvre
authors.forename: Martine
authors.initials: M
authors.lastname: De Pauw
authors.forename: Tony
authors.initials: T
authors.lastname: Vangeneugden
authors.forename: Wim
authors.initials: W
authors.lastname: van den Brink
authors.forename: Richard
authors.initials: R
authors.lastname: Hoetelmans
mesh_terms: D000328:Adult; D000701:Analgesics, Opioid / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D002047:Buprenorphine / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D000069454:Darunavir; D004347:Drug Interactions; D005260:Female; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D006801:Humans; D008297:Male; D008691:Methadone / Q000009:adverse effects / Q000493:pharmacokinetics*; D008875:Middle Aged; D009270:Naloxone / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D009292:Narcotic Antagonists / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D058850:Opiate Substitution Treatment / Q000379:methods; D019438:Ritonavir / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D013449:Sulfonamides / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*
chemical_list: D000701:Analgesics, Opioid; D017320:HIV Protease Inhibitors; D009292:Narcotic Antagonists; D013449:Sulfonamides; D009270:Naloxone; D002047:Buprenorphine; D019438:Ritonavir; D008691:Methadone; D000069454:Darunavir